Abstract The United States Food and Drug Administration (US FDA) has always been a
forerunner in drug evaluation and supervision. Over the past 31 years, 1050 drugs …

The twenty-first century is presenting humankind with unprecedented environmental and
medical challenges. The ability to design novel proteins tailored for specific purposes would …

Anti-epidermal growth factor receptor (EGFR) monoclonal antibodies are approved for the
treatment of RAS wild-type (WT) metastatic colorectal cancer (mCRC), but the emergence of …

During the course of tumorigenesis and subsequent metastasis, malignant cells gradually
diversify and become more heterogeneous. Consequently, the tumor mass might be …

Resistance to anticancer therapies includes primary resistance, usually related to lack of
target dependency or presence of additional targets, and secondary resistance, mostly …

An increasing number of studies are describing potential uses of circulating tumour DNA
(ctDNA) in the care of patients with colorectal cancer. Owing to this rapidly develo** area …

The physiological function of the epidermal growth factor receptor (EGFR) is to regulate
epithelial tissue development and homeostasis. In pathological settings, mostly in lung and …

During cancer progression and treatment, multiple subclonal populations of tumour cells
compete with one another, with selective pressures leading to the emergence of …

Critical driver genomic events in colorectal cancer have been shown to affect the response
to targeted agents that were initially developed under the'one gene, one drug'paradigm of …

Importance Based on a small retrospective study, rechallenge with cetuximab-based therapy
for patients withKRASwild-type metastatic colorectal cancer (mCRC) who were previously …